Bimzelx (also known by its generic name bimekizumab-bkzx) is a biologic medication that was approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy in 2023 and adults living with active psoriatic arthritis in 2024.

Bimzelx is given by injection. For adults with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment), weeks 4, 8, 12, and 16, and then every 8 weeks afterward.

To learn more, please visit the Bimzelx website.

Last updated on 3/24/25 by the National Psoriasis Foundation.